GBIO - Generation Bio Co.


5.34
-0.400   -7.491%

Share volume: 551,924
Last Updated: 02-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.14%

PREVIOUS CLOSE
CHG
CHG%

$5.74
-0.40
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
38%
Profitability 35%
Dept financing 33%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0.95%
6 Months
-8.40%
1 Year
978.79%
2 Year
52.14%
Key data
Stock price
$5.34
P/E Ratio 
0.00
DAY RANGE
$5.34 - $5.70
EPS 
-$1.59
52 WEEK RANGE
$0.30 - $6.95
52 WEEK CHANGE
$978.79
MARKET CAP 
41.222 M
YIELD 
N/A
SHARES OUTSTANDING 
6.738 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
2.76
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
$551,924
Company detail
CEO: Cameron G. McDonough
Region: US
Website: generationbio.com
Employees: 150
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Generation Bio Co. develops therapies for the treatment of rare and prevalent diseases. The company was formerly known as Torus Therapeutics, Inc. It focuses on the diseases of skeletal muscle, central nervous system, and oncology.

Recent news